Literature DB >> 29590332

Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons.

Philip E Tarr1, Bruno Ledergerber2, Alexandra Calmy3, Thanh Doco-Lecompte3, Alex Marzel2, Rainer Weber2, Philipp A Kaufmann4, René Nkoulou5, Ronny R Buechel4, Helen Kovari2.   

Abstract

Aims: HIV-positive persons have increased cardiovascular event rates but data on the prevalence of subclinical atherosclerosis compared with HIV-negative persons are not uniform. We assessed subclinical atherosclerosis utilizing coronary artery calcium (CAC) scoring and coronary computed tomography angiography (CCTA) in 428 HIV-positive participants of the Swiss HIV Cohort Study and 276 HIV-negative controls concurrently referred for clinically indicated CCTA. Methods and results: We assessed the association of HIV infection, cardiovascular risk profile, and HIV-related factors with subclinical atherosclerosis in univariable and multivariable analyses. HIV-positive participants (median duration of HIV infection, 15 years) were younger than HIV-negative participants (median age 52 vs. 56 years; P < 0.01) but had similar median 10-year Framingham risk scores (9.0% vs. 9.7%; P = 0.40). The prevalence of CAC score >0 (53% vs. 56.2%; P = 0.42) and median CAC scores (47 vs. 47; P = 0.80) were similar, as was the prevalence of any, non-calcified/mixed, and high-risk plaque. In multivariable adjusted analysis, HIV-positive participants had a lower prevalence of calcified plaque than HIV-negative participants [36.9% vs. 48.6%, P < 0.01; adjusted odds ratio (aOR) 0.57; 95% confidence interval (CI) 0.40-0.82; P < 0.01], lower coronary segment severity score (aOR 0.72; 95% CI 0.53-0.99; P = 0.04), and lower segment involvement score (aOR 0.71, 95% CI 0.52-0.97; P = 0.03). Advanced immunosuppression was associated with non-calcified/mixed plaque (aOR 1.97; 95% CI 1.09-3.56; P = 0.02).
Conclusion: HIV-positive persons in Switzerland had a similar degree of non-calcified/mixed plaque and high-risk plaque, and may have less calcified coronary plaque, and lower coronary atherosclerosis involvement and severity scores than HIV-negative persons with similar Framingham risk scores.

Entities:  

Mesh:

Year:  2018        PMID: 29590332     DOI: 10.1093/eurheartj/ehy163

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  16 in total

1.  Association of HIV Infection With Cardiovascular Pathology Based on Advanced Cardiovascular Imaging: A Systematic Review.

Authors:  Jonathan A Hudson; Edith D Majonga; Rashida A Ferrand; Pablo Perel; Shirjel R Alam; Anoop S V Shah
Journal:  JAMA       Date:  2022-09-13       Impact factor: 157.335

2.  Caspase-1 Activation Is Related With HIV-Associated Atherosclerosis in an HIV Transgenic Mouse Model and HIV Patient Cohort.

Authors:  Alison C Kearns; Fengming Liu; Shen Dai; Jake A Robinson; Elizabeth Kiernan; Lediya Tesfaye Cheru; Xiao Peng; Jennifer Gordon; Susan Morgello; Aishazhan Abuova; Janet Lo; Markella V Zanni; Steven K Grinspoon; Tricia H Burdo; Xuebin Qin 秦学斌
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-07-18       Impact factor: 8.311

Review 3.  Coronary artery disease in patients with human immunodeficiency virus infection.

Authors:  Pratik Mondal; Ahmed Aljizeeri; Gary Small; Saurabh Malhotra; Prakash Harikrishnan; Jacquita S Affandi; Ronny R Buechel; Girish Dwivedi; Mouaz H Al-Mallah; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2020-08-20       Impact factor: 5.952

4.  HIV and Coronary Atherosclerosis: Research Separates Association from Causation.

Authors:  Shenghan Lai
Journal:  Radiology       Date:  2021-04-20       Impact factor: 29.146

5.  Cardiovascular risk factors and illicit drug use may have a more profound effect on coronary atherosclerosis progression in people living with HIV.

Authors:  Márton Kolossváry; Elliot K Fishman; Gary Gerstenblith; David A Bluemke; Raul N Mandler; David Celentano; Thomas S Kickler; Sarah Bazr; Shaoguang Chen; Shenghan Lai; Hong Lai
Journal:  Eur Radiol       Date:  2021-03-03       Impact factor: 7.034

Review 6.  Coronary Artery Disease in Patients with HIV Infection: An Update.

Authors:  Amish A Patel; Matthew J Budoff
Journal:  Am J Cardiovasc Drugs       Date:  2020-11-13       Impact factor: 3.283

Review 7.  Contribution of Behavioral Health Factors to Non-AIDS-Related Comorbidities: an Updated Review.

Authors:  Natalie E Chichetto; Brittanny M Polanka; Kaku A So-Armah; Minhee Sung; Jesse C Stewart; John R Koethe; E Jennifer Edelman; Hilary A Tindle; Matthew S Freiberg
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.495

Review 8.  How Monocytes Contribute to Increased Risk of Atherosclerosis in Virologically-Suppressed HIV-Positive Individuals Receiving Combination Antiretroviral Therapy.

Authors:  Anthony Jaworowski; Anna C Hearps; Thomas A Angelovich; Jennifer F Hoy
Journal:  Front Immunol       Date:  2019-06-19       Impact factor: 7.561

9.  Utility of routine non-gated CT chest in detection of subclinical atherosclerotic calcifications of coronary arteries in hospitalised HIV patients.

Authors:  Mayil Krishnam; Eun Jin Chae; Eduardo Hernandez-Rangel; Edgar Karangiah; Geeta Gupta; Mathew Budoff
Journal:  Br J Radiol       Date:  2020-02-28       Impact factor: 3.039

10.  Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate.

Authors:  Gregory D Huhn; David J Shamblaw; Jean-Guy Baril; Priscilla Y Hsue; Brittany L Mills; Thai Nguyen-Cleary; Scott McCallister; Moupali Das
Journal:  Open Forum Infect Dis       Date:  2019-11-11       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.